cd147-cart
Glioblastoma
Xijing HospitalCell therapyEarly Phase 1Dormant
C
38/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 81/ 100
Competitive context
354 Active assets in the Glioblastoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Depatuxizumab Mafodotin AbbVie | Phase 3 | BB |
Irinotecan University of Cincinnati | Phase 3 | BB |
(+)-VINCRISTINE University of Cincinnati | Phase 3 | BB |
CARMUSTINE Leland Metheny | Phase 3 | BB |
Cintredekin Besudotox INSYS Therapeutics Inc | Phase 3 | BB |
View all 50 →
Same molecule, other indications
cd147-cart is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →